• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Cipla Ltd.
    22 Aug 2025, 07:23AM
    1527.10
    -0.98%
    Looking for short-term F&O trade? Check this 'Bull Spread' on Cipla
    Business Standard
    Short term trend is positive as it is placed above its 5, 11 and 20 day EMA Stock price has broken out on the weekly chart with higher volumes
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. is trading below its 30 day SMA of 1563.2
    logo
    Caplin Point Laboratories Ltd.
    22 Aug 2025, 06:45AM
    2253.60
    -2.86%
    Stock Market Live Updates 22 August 2025: Stock to buy today: Caplin Point Laboratories
    Business Line
    Sensex, Nifty, Share Prices LIVE: The short-term outlook is bullish for Caplin Point Laboratories. The 4 per cent rise has taken the share price well above the 2,130-2,140 resistance zone. This region will now act as a good support and limit the downside. Below this 2,080 will be the next important support. Immediate resistance is at 2,230 which can be broken in the next few days. Such a break can take Caplin Point Laboratories share price up to 2,330 in the coming weeks. Traders can buy Caplin Point Laboratories now at 2,205. Accumulate on dips at 2,160. Keep the stop-loss at 2,110 initially. Trail the stop-loss up to 2,225 as soon as the stock goes up to 2,255. Move the stop-loss further up to 2,260 and 2,285 when the price touches 2,280 and 2,300 respectively. Exit the long positions at 2,320.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 177 to 198 in Jun 2025 qtr.
    Stock to buy today: Caplin Point Laboratories (2,205) BUY
    Business Line | 22 Aug 2025, 06:30AM
    logo
    Granules India Ltd.
    22 Aug 2025, 06:30AM
    523.80
    -0.48%
    Can Granules India leverage its strong product pipeline to offset recent profit declines?
    Can Granules India leverage its strong product pipeline to offset recent profit declines?
    Economic Times
    Granules India's stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the company's product pipeline and business stabilisation. The company anticipates better growth in FY27. Approvals for six products in Europe are awaited. Granules focuses on CNS, ADHD, and oncology products. The Gagillapur facility remediation is progressing well with US FDA.
    Copy LinkShare onShare on Share on Share on
    Geojit BNP Paribas increased Accumulate price target of Granules India Ltd. to 630.0 on 18 Sep, 2025.
    logo
    Sai Life Science Ltd.
    20 Aug 2025
    892.25
    2.05%
    Sai Life Sciences secures SBTi validation for near-term climate targets
    Business Line
    Sai Life Sciences has committed to reduce absolute scope 1 and 2 GHG emissions 58.8% by FY35 with FY24 as base year
    Copy LinkShare onShare on Share on Share on
    Mutual Funds have increased holdings from 11.54% to 18.73% in Jun 2025 qtr.
    logo
    Aurobindo Pharma Ltd.
    20 Aug 2025
    1109.90
    -0.67%
    Aurobindo Pharma leads $5 billion race to acquire Prague-based Zentiva
    Business Standard
    Shortly after reports of the potential acquisition surfaced, Aurobindo clarified that no binding agreement or definitive decision has been made regarding the deal
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings
    logo
    Natco Pharma Ltd.
    20 Aug 2025
    855.50
    -1.04%
    Natco Pharma introduces generic Bosentan in US for pulmonary arterial hypertension treatment
    Business Line
    Natco received USFDA approval for its ANDA and secured the coveted first-to-file status, granting it 180-day generic drug exclusivity
    Copy LinkShare onShare on Share on Share on
    Natco Pharma Ltd. has an average target of 1294.50 from 4 brokers.
    logo
    Glenmark Pharmaceuticals Ltd.
    19 Aug 2025
    Board Meeting
    2016.80
    -0.05%
    'Buy' Glenmark Pharma Shares Maintains Motilal Oswal Despite Weak Q1 Results Check Target Price
    'Buy' Glenmark Pharma Shares Maintains Motilal Oswal Despite Weak Q1 Results Check Target Price
    NDTV Profit
    Motilal Oswal maintain 'Buy' rating on Glenmark Pharma and hikes target price sees strategic transformation to be underway
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2019.0
    Glenmark Pharma Eyes 19-20% Ebitda Margin In FY26 Driven By Strong Performance Across Markets
    NDTV Profit | 19 Aug 2025 1 more
    Glenmark Pharma falls 5% in 2 days on Q1 show; Here's what analysts suggest
    Business Standard | 19 Aug 2025
    logo
    Alembic Pharmaceuticals Ltd.
    19 Aug 2025
    940.05
    -1.05%
    Alembic Pharma shares rise 2% on pulmonary hypertension drug approval
    Business Standard
    Alembic Pharma shares rose 2.3 per cent on Tuesday, after the company received US Food & Drug Administration (USFDA) final approval for its Abbreviated New Drug Application (ANDA) Macitentan Tablets
    Copy LinkShare onShare on Share on Share on
    Alembic Pharmaceuticals Ltd. is trading below all available SMAs
    logo
    Marksans Pharma Ltd.
    18 Aug 2025
    Drug Approval
    171.32
    -1.68%
    Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here
    Business Standard
    The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem in the UK, had received marketing authorisation for its products
    Copy LinkShare onShare on Share on Share on
    Marksans Pharma Ltd. is trading below all available SMAs
    logo
    Alembic Ltd.
    18 Aug 2025
    104.33
    -0.74%
    Alembic gets USFDA nod for generic drug for skin condition
    Business Line
    The company has received final approval from the US Food & Drug Administration for its abbreviated new drug application for Tretinoin Cream USP, the drug maker said in a statement
    Copy LinkShare onShare on Share on Share on
    Alembic Ltd. has lost -26.93% in the last 1 Year
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • GK Energy
    • Saatvik Green Energy
    • Siddhi Cotspin
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd